Sol-Gel Technologies Ltd. (SLGL) News
Filter SLGL News Items
SLGL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SLGL News From Around the Web
Below are the latest news stories about SOL-GEL TECHNOLOGIES LTD that investors may wish to consider to help them evaluate SLGL as an investment opportunity.
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should KnowSolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid RequirementNESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s ("Nasdaq") minimum bid pric |
Sol-Gel Technologies Third Quarter 2024 Earnings: Beats ExpectationsSol-Gel Technologies ( NASDAQ:SLGL ) Third Quarter 2024 Results Key Financial Results Revenue: US$5.36m (up by US$5.15m... |
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue EstimatesSolGel Technologies (SLGL) delivered earnings and revenue surprises of 92.31% and 99.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesMori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-6 |
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAfter losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong BuySolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Sol-Gel Technologies Second Quarter 2024 Earnings: Beats ExpectationsSol-Gel Technologies ( NASDAQ:SLGL ) Second Quarter 2024 Results Key Financial Results Revenue: US$5.43m (up by... |
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesFollowing recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoingSol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug |
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue EstimatesSolGel Technologies (SLGL) delivered earnings and revenue surprises of 135% and 414.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? |